Cardiovascular drug therapy in the elderly

Tresch and Aronow's Cardiovascular Disease in the Elderly

Volumn , Issue , 2013, Pages 67-103

  Frishman, William H ^a   Aronow, Wilbert S ^a   Cheng Lai, Angela ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85130889751     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Fleg JL, Aronow WS, Frishman WF. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011; 8: 13-28.
2. Frishman WH. Basic principles of clinical pharmacology relevant to cardiology. In: Frishman WH, Sonnenblick EH, Sica D, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 3-15.
3. Castleden CM, George CF. The effect of aging on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 7: 49-54.
4. Rubin PC, Scott PJW, Reid JL. Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol 1981; 12: 401-4.
5. Novak LP. Aging, total body potassium, fat-free mass and cell mass in males and females between the ages of 18 and 85 years. J Gerontol 1972; 27: 438-43.
6. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425-32.
7. Cusack B, Kelly J, O'Malley K, et al. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol 1979; 2: 722-6.
8. Abernethy DR, Kerzner L. Age effects on alpha-1 acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc 1984; 32: 705-8.
9. Holt DW, Hayler AM, Healey GF. Effect of age and plasma concentrations of albumin and alpha-1 acid glycoprotein on protein binding of disopyramide. Br J Clin Pharmacol 1983; 16: 344-5.
10. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985; 37: 133-48.
11. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age. II. Phenytoin clearance and protein binding. Br J Clin Pharmacol 1975; 2: 73-9.
12. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297-301.
13. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in man: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63.
14. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192-8.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
17. Sica DA. Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992; 20: S13-20.
18. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert consensus document on hypertension in the elderly. A report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol 2011; 57: 2037-114.
19. Abernethy DR, Schwartz JB, Plachetka JR, et al. Comparison of young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. Am J Cardiol 1987; 60: 697-702.
20. Dillon N, Chung S, Kelly J, O'Malley K. Age and beta-adrenoceptor mediated function. Clin Pharmacol Ther 1980; 27: 769-72.
21. Vestal RE, Wood AJJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979; 26: 181-6.
22. Scarpace PJ, Armbrecht HJ. Adenylate cyclase in senescence: catecholamine and parathyroid hormone pathways. Rev Clin Basic Pharmacol 1987; 6: 105-18.
23. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
24. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 women in a long-term health care facility. J Gerontol Med Sci 2002; 57A: M45-6.
25. Aronow WS, Mercando AD, Epstein S. Prevalence of arrhythmias detected by 24 hour ambulatory electrocardiography and value of antiarrhythmic therapy in elderly patients with unexplained syncope. Am J Cardiol 1992; 70: 408-10.
26. Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: which is the preferred treatment? Drugs Aging 1991; 1: 98-103.
27. Butler VP Jr, Odel JG, Rath E, et al. Digitalis-induced visual disturbances with therapeutic serum digitalis concentrations. Ann Intern Med 1995; 123: 676-80.
28. Hunt SA, Abraham WT, Feldman AM, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation 2005; 112: 1825-52.
29. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol 1999; 84: 611-12.
30. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137: 631-9.
31. Aronow WS. Echocardiography should be performed in all elderly patients with congestive heart failure. J Am Geriatr Soc 1994; 42: 1300-2.
32. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982; 73: 244-50.
33. Aronow WS, Starling L, Etienne F. Lack of efficacy of digoxin in treatment of compensated congestive heart failure with third heart sound and sinus rhythm in elderly patients receiving diuretic therapy. Am J Cardiol 1986; 58: 168-9.
34. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11.
35. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-8.
36. Ahmed A, Aronow WS, Fleg JL. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Ther 2006; 13: 325-31.
37. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Failure 2006; 8: 409-19.
38. LeJemtel TH, Klapholz M, Frishman WH. Inotropic agents. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 189-203.
39. Galun E, Flugelman MY, Glickson M, Eliakim M. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991; 99: 1038-40.
40. Moss AJ, Davis HT, Conard DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981; 64: 1150-6.
41. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55: 623-30.
42. Leor J, Goldbourt U, Rabinowitz B, et al. Does digoxin exert adverse effects on survivors of myocardial infarction? The importance of digoxin dose (abst). J Am Coll Cardiol 1994; 23: 113A.
43. Byington R, Goldstein S; BHAT Research Group. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observation of the Beta Blocker Heart Attack Trial. J Am Coll Cardiol 1985; 6: 976-82.
44. Muller JE, Turi ZG, Stone PH, et al. Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. N Engl J Med 1986; 314: 265-71.
45. Eberhardt RT, Frishman WH, Landau A, et al. Increased mortality incidence in elderly individuals receiving digoxin therapy: results from the Bronx Longitudinal Aging Study. Cardiol Elderly 1995; 3: 177-82.
46. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
47. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289: 2560-72.
48. SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). J Am Med Assoc 1991; 265: 3255-64.
49. The CONSENSUS Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
50. Sica DA, Gehr TWB, Frishman WH. Diuretic therapy in cardiovascular disease. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 157-75.
51. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
52. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7.
53. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nevibilol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
54. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71: 602-4
55. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol 1997; 80: 207-9.
56. Sica DA, Gehr TW. Diuretic combinations in refractory edema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30: 229-49.
57. Sica DA, Gehr TWB. Drug absorption in congestive heart failure: loop diuretics. Congestive Heart Failure 1998; 5: 37-43.
58. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160: 777-84.
59. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-30.
60. Baglin A, Boulard JC, Hanslik T, Prinseau J. Metabolic adverse reactions to diuretics. Clinical relevance to elderly patients. Drug Safety 1995; 12: 161-7.
61. Frishman WH, Sonnenblick EH. Beta-adrenergic blocking drugs and calcium channel blockers. In: Alexander RW, Schlant RC, Fuster V, eds. The Heart, 9th edn. New York: McGraw Hill, 1998: 1583-618.
62. Sica DA. Old antihypertensive agents - diuretics and ß-blockers - do we know how and in whom they lower blood pressure. Curr Hypertens Rep 1999; 1: 296-304.
63. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. J Am Med Assoc 1993; 270: 1589-95.
64. Hawkins CM, Richardson DW, Vokonas PS; BHAT Research Group. Effect of propranolol in reducing mortality in older myocardial infarction patients: the Beta Blocker Heart Attack Trial experience. Circulation 1983; 67: I-94-I97.
65. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients aged 65-75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179-84.
66. Park KC, Forman DE, Wei JY. Utility of β blocker treatment for older post-infarction patients. J Am Geriatr Soc 1995; 43: 751-5.
67. Gurwitz JH, Goldberg RJ, Chen Z, et al. Beta blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med 1992; 93: 605-10.
68. Mendelson G, Aronow WS. Underutilization of beta blockers in older patients with prior myocardial infarction or coronary artery disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1997; 45: 1360-1.
69. Frishman WH. ß-Adrenergic blockers: a 50 year historical perspective. Am J Ther 2008; 15: 565-76.
70. Hansteen V. Beta blockade after myocardial infarction: the norwegian propranolol study in high-risk patients. Circulation 1983; 67: I-57-60.
71. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients >62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction >40%. Am J Cardiol 1994; 74: 267-70.
72. Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994; 74: 613-15.
73. Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984; 2: 883-6.
74. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 1990; 82: 1962-72.
75. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 1991; 68: 1025-31.
76. Aronow WS, Ahn C, Mercando AD, Epstein S. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994; 74: 819-21.
77. Kennedy HL, Brooks MM, Barker AH, et al. Beta blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994; 74: 674-80.
78. Frishman WH. Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 57-85.
79. Aronow WS. Management of the older person with atrial fibrillation. J Gerontol Med Sci 2002; 57A: M352-63.
80. Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983; 83: 491-9.
81. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316-24.
82. David D, DiSegni E, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta-adrenergic blocking agent. Am J Cardiol 1979; 44: 1378-82.
83. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
84. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
85. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 2001; 344: 651-8.
86. Frishman WH. Carvedilol: a new alpha- and beta-adrenoceptor blocker for the treatment of congestive heart failure. N Engl J Med 1998; 339: 1759-65.
87. Aronow WS. Effect of beta blockers on mortality and morbidity in persons treated for congestive heart failure. J Am Geriatr Soc 2001; 49: 331-3.
88. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive ß blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA 1995; 274: 1611-13.
89. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
90. Pfeffer MA, Braunwald E, Moye LA, et al. On Behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity of patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
91. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
92. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-18.
93. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001; 88: 1298-300.
94. Schoolwerth A, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation 2001; 104: 1985-91.
95. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
96. Okereke CE, Messerli FH. Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. Am J Geriatr Cardiol 2001; 10: 424-9.
97. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 2: 402-11.
98. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000; 160: 1905-11.
99. Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev 2011; 19: 300-4.
100. Toto R. Angiotensin II subtype 1-receptor blockers and renal function. Arch Intern Med 2001; 161: 1492-9.
101. Jamali AH, Tang WH, Khot UN, Fowler MB. The role of angiotensin receptor blockers in the management of chronic heart failure. Arch Intern Med 2001; 161: 667-72.
102. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
103. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
104. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
105. Sepehrdad R, Stier CT Jr, Frishman WH, Sica DA. Specific inhibition of renin as a cardiovascular pharmacotherapy: focus on Aliskiren. Cardiol Rev 2007; 15: 242-56.
106. Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49: 29-31.
107. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67: 1767-92.
108. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006; 79: 64(PIII-24).
109. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 58: 433-6.
110. Pahor M, Cecchi E, Fumagalli S, et al. Association of serum creatinine and age with headache caused by nitrates. Gruppo Italiano di Farmacovigilanza nell' Anziano. Clin Pharmacol Ther 1995; 59: 470-81.
111. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? Arch Intern Med 1995; 155: 2157-61.
112. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7.
113. Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? J Am Geriatr Soc 1995; 43: 1309-10.
114. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo vs active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Lancet 1997; 350: 757-64.
115. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
116. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981-6.
117. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-61.
118. The Multicenter Diltiazem Post Infarction Trial Research Group. Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92.
119. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992; 22: 416-33.
120. Frishman WH. Alpha- and beta adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH. Cardiovascular Pharmacotherapeutics, Companion Handbook. New York: McGraw Hill, 1998: 23-64.
121. Frishman WH, Kotob F. Alpha-adrenergic blocking drugs in clinical practice. J Clin Pharmacol 1999; 39: 7-16.
122. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75.
123. Zimetbaum P, Kowey PR, Michelson EL. Antiarrhythmic drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 227-56.
124. Ochs HR, Carstens G, Greenblatt DJ. Reduction of lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980; 303: 373-7.
125. Aronow WS. Management of the person with ventricular arrhythmias. J Am Geriatr Soc 1999; 47: 886-95.
126. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
127. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33.
128. Akiyama T, Pawitan Y, Campbell WB, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. J Am Geriatr Soc 1992; 40: 666-72.
129. Moosvi AR, Goldstein S, Vanderbrug Medendorp S, et al. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. Am J Cardiol 1990; 65: 1192-7.
130. Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine and procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1990; 66: 423-8.
131. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
132. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-32.
133. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016-21.
134. Hockings B, George T, Mahrous F, et al. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol 1987; 60: 967-70.
135. Pfisterer M, Kiowski W, Burckhardt D, et al. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399-402.
136. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74.
137. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82.
138. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8.
139. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995; 333: 77-82.
140. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
141. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-9.
142. Greene HL for the CASCADE Investigators. The CASCADE study: randomized anti-arrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993; 72: 70F-4F.
143. Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-7.
144. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012; 110: 607-13.
145. LaRosa JC, Applegate W, Crouse JR III, et al. Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154: 529-39.
146. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participantys in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
147. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
148. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-18.
149. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681-9.
150. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
151. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-87.
152. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
153. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92: 711-12.
154. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 89: 67-9.
155. Aronow WS, Ahn C, Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. J Gerontol Med Sci 2002; 57A: M333-5.
156. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90: 147-9.
157. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and of new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins. J Gerontol Med Sci 2002; 57A: M747-50.
158. Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90: 789-91.
159. Zimetbaum P, Frishman WH, Ooi WL, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the old old: Bronx Longitudinal Aging Study. Arterio Thrombo 1992; 12: 416-23.
160. Collins R, Armitage J. High-risk elderly patients PROSPER from cholesterol-lowering therapy (commentary). Lancet 2002; 360: 1618-19.
161. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
162. Frishman WH, Aronow WS. Lipid-lowering drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 323-75.
163. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80.
164. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
165. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
166. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
167. Sebastian JL, Tresch D. Anticoagulation therapy in the elderly. In: Fresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient. New York: Marcel Dekker Inc, 1994: 213-61.
168. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulation therapy in elderly patients after myocardial infarction: report of the sixty plus reinfarction study research group. Lancet 1980; 2: 989-94.
169. Shepherd AMM, Hewick DS, Moreland TA, Stevenson TH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20.
170. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
171. Frishman WH, Lerner RG, Desai H. Antiplatelet and other antithrombotic drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 257-304.
172. Bhatt DL. Prasugrel in clinical practice (perspective). N Engl J Med 2009; 361: 940-2.
173. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
174. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
175. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
176. Frishman WH, Sinatra ST, Moizuddin M. Herbal approach to cardiac disease. In: Frishman WH, Weintraub MI, Micozzi MS, eds. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis: Elsevier/Mosby, 2005: 86-106.
177. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825-32.
178. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992; 117: 684-9.
179. Beers MH, Fingold SF, Ouslander JG, et al. Characteristics and quality of prescribing by doctors practicing in nursing homes. J Am Geriatr Soc 1993; 41: 802-7.
180. Stuck AE, Beers MH, Steiner A, et al. Inappropriate medication use in community-residing older persons. Arch Intern Med 1994; 154: 2195-200.
181. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272: 292-6.
182. Gurwitz JH. Suboptimal medication use in the elderly: the tip of the iceberg. JAMA 1994; 272: 316-17.
183. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157: 1531-6.
184. Johnson JF. Considerations in Prescribing for the Older Patient. Arizona: PCS Health Systems, Inc, 1998; 1/98.
185. Abrams WB. Cardiovascular drugs in the elderly. Chest 1990; 98: 9809-86.
186. Stein BE. Avoiding drug reactions: seven steps to writing safe prescriptions. Geriatrics 1994; 49: 28-36.
187. Nagle BA, Erwin WG. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy. A Patho-physiologic Approach, 3rd edn. Stamford: Appleton and Lange, 1997: 87-100.
188. Hui KK. Gerontologic considerations in cardiovascular pharmacology and therapeutics. In: Singh BN, Dzau VJ, Vanhoutte PM, et al. eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill-Livingstone, 1994: 1130.
189. Cheng-Lai A, Frishman WH. Appendices. Cardiovascular Pharmacotherapeutics, 3rd edn. Minneapolis: Cardiotext, 2011: 745-9.
190. Aronow WS. Cardiovascular drug therapy in the elderly. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: McGraw-Hill, 1997: 1273.
191. Parker BM, Cusack BJ. Pharmacology and appropriate prescribing. In: Reuben DB, Yoshikawa TT, Besdine RW, eds. Geriatric Review Syllabus: A Core Curriculum in Geriatric Medicine, 3rd edn. Iowa: Kendall/Hunt Publishers, Am Geriatric Soc, 1996: 33.
192. Bressler R. Adverse drug reactions. In: Bressler R, Katz MD, eds. Geriatric Pharmacology. New York: McGraw-Hill, 1993: 54.
193. Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet 1997; 33: 79-90.
194. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg JL, Rich MW. Cardiovascular Disease in the Elderly, 4th edn. New York: Informa, 2008: 99-135.
195. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157: 1531-6.